CAMBRIDGE, Mass.--(BUSINESS WIRE)--Innovations in genomics technology have made the genetic information of individuals very accessible. This information, in turn, is being used in a growing array of diagnostic and treatment-tuning capacities.
On Friday, February 28, the MIT Sloan BioInnovations Conference will bring together industry, academic and policy leaders to address trends and new approaches to precision medicine along with the impact of big data on healthcare, innovative financing, and new opportunities in emerging markets. The conference will be held at the Boston Marriott Cambridge hotel in Kendall Square.
Slated keynote speakers are:
- Dr. Margaret Hamburg, Commissioner, Food and Drug Administration
- Dr. George Church, Wyss Institute of Synthetic Biology & Director of Personal Genome Project
- Alex Azar, President, Lilly USA, LLC at Eli Lilly and Company
- Kieran Murphy, President and CEO, GE Healthcare Life Sciences
Four panels will focus on:
Innovation Trends in Upstream R&D and Phase I Pipeline Development
A
look at pre-competitive consortia of pharma companies, big-data-related
methods of generating or capturing chemical and biological diversity,
and novel therapeutic modalities such as RNA interference, gene therapy,
cell therapy and viral therapy.
Big Data in Healthcare: Where Does That Lead Us?
A look at
the wealth of opportunities and challenges brought on by big data, and
how players in the healthcare industry are seeking to capitalize on this
information to help drive more innovation to improve healthcare outcomes.
Seizing Uncaptured Opportunities in Emerging Markets
Common
challenges around regulation, distribution, access, and affordability
across diverse emerging markets, as well as innovative approaches in
addressing these challenges will be explored.
Transforming Healthcare Entrepreneurship with Innovative Financing
The
transformation of the US healthcare system has created a paradigm shift
in how start-ups are seeded, grown, and assessed. This panel will
encourage discussion on innovative approaches to grow and finance
healthcare ventures.
For more information and to register, please visit: http://web.mit.edu/sloanhcc/bioinnovations/2014/.
About the MIT Sloan BioInnovations Conference
The MIT Sloan
BioInnovations conference has established itself as an important forum
for leaders in industry, academia, and policy to discuss current issues
and future innovations in the dynamic area of healthcare, from
healthcare in emerging markets to new drug technologies. Participants
will hear from industry leaders in keynote addresses and panel
discussions, will view new technological and business innovations from
the many biomedical institutes and startups around Boston through poster
presentations, and will have the opportunity to network with
professionals and students from a variety of disciplines.